Replies to post #407541 on Amarin Corp Plc (AMRN)

[JRoon71]

I think combo drug is non-starter in U.S. Not sure why any insurance company would pay for it, when they already pay for statins individually. Plus, many people have preference/tolerance for specific statins.

I mean, I suppose it could sell some scripts (if insurance reimburses for it). But I just don't know to what degree.

I DO think MND-2019 has huge potential to re-claim U.S. Market. I just wish we knew what the status was of that drug.